Medicare Claims To Be Used To Monitor Drugs For Post-Market Adverse Events

The Food and Drug Administration (FDA) recently launched an initiative to use information from Medicare Part D claims to investigate the performance of drugs on the market and rapidly identify potential adverse events. The program, termed the Sentinel Initiative, will allow the FDA to detect post-market problems with drugs as they arise.

More: continued here

Filed under: Pharma Industry on June 10th, 2008